271 related articles for article (PubMed ID: 30923816)
1. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
Gane E; Poordad F; Zadeikis N; Valdes J; Lin CW; Liu W; Asatryan A; Wang S; Stedman C; Greenbloom S; Nguyen T; Elkhashab M; Wörns MA; Tran A; Mulkay JP; Setze C; Yu Y; Pilot-Matias T; Porcalla A; Mensa FJ
Clin Infect Dis; 2019 Oct; 69(10):1657-1664. PubMed ID: 30923816
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
Flamm S; Reddy KR; Zadeikis N; Hassanein T; Bacon BR; Maieron A; Zeuzem S; Bourliere M; Calleja JL; Kosloski MP; Oberoi RK; Lin CW; Yu Y; Lovell S; Semizarov D; Mensa FJ
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):527-535.e6. PubMed ID: 30012435
[TBL] [Abstract][Full Text] [Related]
3. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
[TBL] [Abstract][Full Text] [Related]
4. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
[TBL] [Abstract][Full Text] [Related]
5. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
Naganuma A; Chayama K; Notsumata K; Gane E; Foster GR; Wyles D; Kwo P; Crown E; Bhagat A; Mensa FJ; Otani T; Larsen L; Burroughs M; Kumada H
J Gastroenterol; 2019 Aug; 54(8):752-761. PubMed ID: 30868245
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Asselah T; Kowdley KV; Zadeikis N; Wang S; Hassanein T; Horsmans Y; Colombo M; Calinas F; Aguilar H; de Ledinghen V; Mantry PS; Hezode C; Marinho RT; Agarwal K; Nevens F; Elkhashab M; Kort J; Liu R; Ng TI; Krishnan P; Lin CW; Mensa FJ
Clin Gastroenterol Hepatol; 2018 Mar; 16(3):417-426. PubMed ID: 28951228
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis.
Lampertico P; Carrión JA; Curry M; Turnes J; Cornberg M; Negro F; Brown A; Persico M; Wick N; Porcalla A; Pangerl A; Crown E; Larsen L; Yu Y; Wedemeyer H
J Hepatol; 2020 Jun; 72(6):1112-1121. PubMed ID: 32061651
[TBL] [Abstract][Full Text] [Related]
9. Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older.
Huff J; Andersen R
Ann Pharmacother; 2020 Mar; 54(3):262-276. PubMed ID: 31537106
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.
Asselah T; Lee SS; Yao BB; Nguyen T; Wong F; Mahomed A; Lim SG; Abergel A; Sasadeusz J; Gane E; Zadeikis N; Schnell G; Zhang Z; Porcalla A; Mensa FJ; Nguyen K
Lancet Gastroenterol Hepatol; 2019 Jan; 4(1):45-51. PubMed ID: 30393106
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Chayama K; Suzuki F; Karino Y; Kawakami Y; Sato K; Atarashi T; Naganuma A; Watanabe T; Eguchi Y; Yoshiji H; Seike M; Takei Y; Kato K; Alves K; Burroughs M; Redman R; Pugatch DL; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Kumada H
J Gastroenterol; 2018 Apr; 53(4):557-565. PubMed ID: 28948366
[TBL] [Abstract][Full Text] [Related]
12. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
Zuckerman E; Gutierrez JA; Dylla DE; de Ledinghen V; Muir AJ; Gschwantler M; Puoti M; Caruntu F; Slim J; Nevens F; Sigal S; Cohen S; Fredrick LM; Pires Dos Santos AG; Rodrigues L; Dillon JF
Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2544-2553.e6. PubMed ID: 32621971
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.
Kosloski MP; Wang H; Pugatch D; Mensa FJ; Gane E; Lawitz E; Marbury TC; Preston RA; Kort J; Liu W
Eur J Clin Pharmacol; 2019 Feb; 75(2):217-226. PubMed ID: 30341499
[TBL] [Abstract][Full Text] [Related]
14. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
Puoti M; Foster GR; Wang S; Mutimer D; Gane E; Moreno C; Chang TT; Lee SS; Marinho R; Dufour JF; Pol S; Hezode C; Gordon SC; Strasser SI; Thuluvath PJ; Zhang Z; Lovell S; Pilot-Matias T; Mensa FJ
J Hepatol; 2018 Aug; 69(2):293-300. PubMed ID: 29551706
[TBL] [Abstract][Full Text] [Related]
15. Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
Flamm S; Mutimer D; Asatryan A; Wang S; Rockstroh J; Horsmans Y; Kwo PY; Weiland O; Villa E; Heo J; Gane E; Ryder SD; Welzel TM; Ruane PJ; Agarwal K; Ng TI; Xue Z; Lovell SS; Krishnan P; Kopecky-Bromberg S; Trinh R; Mensa FJ; Wyles DL
J Viral Hepat; 2019 Mar; 26(3):337-349. PubMed ID: 30421537
[TBL] [Abstract][Full Text] [Related]
16. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
Forns X; Lee SS; Valdes J; Lens S; Ghalib R; Aguilar H; Felizarta F; Hassanein T; Hinrichsen H; Rincon D; Morillas R; Zeuzem S; Horsmans Y; Nelson DR; Yu Y; Krishnan P; Lin CW; Kort JJ; Mensa FJ
Lancet Infect Dis; 2017 Oct; 17(10):1062-1068. PubMed ID: 28818546
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C.
Hsu SJ; Chiu MC; Fang YJ; Yang TH; Yu JJ; Chen CC; Kuo CC; Lee JY; Chen CH; Chen DS; Kao JH
J Formos Med Assoc; 2019 Aug; 118(8):1187-1192. PubMed ID: 31279502
[TBL] [Abstract][Full Text] [Related]
18. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Zeuzem S; Foster GR; Wang S; Asatryan A; Gane E; Feld JJ; Asselah T; Bourlière M; Ruane PJ; Wedemeyer H; Pol S; Flisiak R; Poordad F; Chuang WL; Stedman CA; Flamm S; Kwo P; Dore GJ; Sepulveda-Arzola G; Roberts SK; Soto-Malave R; Kaita K; Puoti M; Vierling J; Tam E; Vargas HE; Bruck R; Fuster F; Paik SW; Felizarta F; Kort J; Fu B; Liu R; Ng TI; Pilot-Matias T; Lin CW; Trinh R; Mensa FJ
N Engl J Med; 2018 Jan; 378(4):354-369. PubMed ID: 29365309
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
Toyoda H; Chayama K; Suzuki F; Sato K; Atarashi T; Watanabe T; Atsukawa M; Naganuma A; Notsumata K; Osaki Y; Nakamuta M; Takaguchi K; Saito S; Kato K; Pugatch D; Burroughs M; Redman R; Alves K; Pilot-Matias TJ; Oberoi RK; Fu B; Kumada H
Hepatology; 2018 Feb; 67(2):505-513. PubMed ID: 28865152
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
Fontana RJ; Lens S; McPherson S; Elkhashab M; Ankoma-Sey V; Bondin M; Dos Santos AGP; Xue Z; Trinh R; Porcalla A; Zeuzem S
Adv Ther; 2019 Dec; 36(12):3458-3470. PubMed ID: 31646465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
